SOLUTION / CARDIOLOGY
Current diagnostic technologies poorly address early detection of Acute Myocardial Infarction (AMI) and Stroke risk
HaimaChek has developed a biomarker probe (BMProbe) for the in vivo isolation of CECs.
Prototypes are already available for academia use.
- Unlike oncology, physicians lack direct access to diseased arterial tissue or other markers to gauge patient risk levels
- Several recent studies have validated circulating endothelial cells (CECs) as a biomarker for vascular injury
HaimaChek has developed a biomarker probe (BMProbe) for the in vivo isolation of CECs.
Prototypes are already available for academia use.